Perspective Therapeutics (NYSEAMERICAN:CATX) Announces Earnings Results

Perspective Therapeutics (NYSEAMERICAN:CATX) released its quarterly earnings results on Monday. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03), FiscalAI reports. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.06 million. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%.

Perspective Therapeutics Stock Performance

NYSEAMERICAN CATX opened at $0.86 on Tuesday. The stock’s 50 day moving average price is $2.29 and its two-hundred day moving average price is $3.48. Perspective Therapeutics has a 52 week low of $0.78 and a 52 week high of $6.16.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on CATX shares. William Blair assumed coverage on shares of Perspective Therapeutics in a research report on Friday, September 18th. They set an “outperform” rating for the company. Wedbush reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a research report on Tuesday. BMO Capital Markets reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a research note on Friday, October 30th. Royal Bank Of Canada lowered shares of Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their target price for the stock from $14.00 to $4.00 in a research note on Monday, October 26th. Finally, Piper Sandler lowered their target price on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Nine investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.50.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc is a biotechnology company developing precision-targeted radiopharmaceutical treatments for cancer. The company’s platform is designed to deliver alpha-particle radiation directly to tumor cells by pairing radioactive isotopes with molecules that bind to specific cancer targets, with the goal of limiting damage to surrounding healthy tissue.

The company’s lead programs include VMT-α-NET, an investigational therapy directed at somatostatin receptor 2, a target commonly expressed by neuroendocrine tumors.